Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 Apr 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 08 May 2026, providing investors with an up-to-date perspective on the company’s fundamentals, returns, and overall outlook.

Aarti Pharmalabs Ltd has exhibited a notable shift in price momentum, moving from a mildly bearish technical trend to a sideways stance, supported by a blend of bullish and bearish signals across key indicators. The stock’s recent surge of 8.26% in a single day to ₹805.70 reflects renewed investor interest, yet technical analysis reveals a complex picture that demands careful scrutiny.

The Sensex gained a modest 0.44% on 4 May 2026, while Aarti Pharmalabs Ltd surged 7.25%, outperforming its Pharmaceuticals & Biotechnology sector by 6.42 percentage points. This sharp single-session advance stands out as a distinctly stock-specific event amid a broadly steady market backdrop.

Aarti Pharmalabs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook.

Aarti Pharmalabs Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 15 April 2026, driven primarily by a shift in technical indicators despite ongoing financial challenges. The company’s Mojo Score now stands at 31.0, reflecting a cautious but slightly more favourable outlook amid persistent operational headwinds and valuation considerations.

Aarti Pharmalabs Ltd has exhibited a subtle shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, reflecting nuanced changes in key indicators such as MACD, RSI, and moving averages. Despite a modest day gain of 1.10%, the stock’s technical signals present a complex picture for investors navigating the Pharmaceuticals & Biotechnology sector.

Aarti Pharmalabs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 02 March 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 05 April 2026, providing investors with the latest insights into the company’s performance and outlook.

The Sensex declined by 2.11% on 1 Apr 2026, while Aarti Pharmalabs Ltd surged 7.05%, marking a remarkable 5.98 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector. This strong single-session gain stands out as a stock-specific event amid a broadly weak market environment.

Aarti Pharmalabs Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 02 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Aarti Pharmalabs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 02 March 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 14 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Aarti Pharmalabs Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. Despite a recent weekly price gain, the stock’s overall technical profile and market performance suggest caution for investors amid weakening momentum and deteriorating technical grades.

Aarti Pharmalabs Ltd has been downgraded from a Sell to a Strong Sell rating as of 2 March 2026, reflecting deteriorating fundamentals and bearish technical indicators. The downgrade follows a comprehensive reassessment across four key parameters: Quality, Valuation, Financial Trend, and Technicals, signalling heightened caution for investors amid ongoing challenges in the pharmaceuticals sector.

Aarti Pharmalabs Ltd commenced trading today with a pronounced gap down, opening at a price 7.31% lower than its previous close, reflecting heightened market apprehension. The stock’s weak start follows a series of mixed technical signals and a downgrade in its Mojo Grade, contributing to a cautious trading environment.

Aarti Pharmalabs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 January 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 26 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Aarti Pharmalabs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Aarti Pharmalabs Ltd experienced a significant intraday decline on 12 Feb 2026, touching a low of Rs 694.5, reflecting a sharp price pressure of -7.78% during the trading session. The stock underperformed its sector and broader market indices, continuing a downward trend over the past three days.